Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3866 | TAK-981 Wiki | 1.00 |
| drug3199 | Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index Wiki | 1.00 |
| drug1935 | Informed consent Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019337 | Hematologic Neoplasms NIH | 0.35 |
| D009369 | Neoplasms, NIH | 0.17 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001909 | Leukemia HPO | 0.27 |
| HP:0002664 | Neoplasm HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
The current COVID-19 pandemic has affected more than 3 million people worldwide across more than 200 countries. In the United Kingdom alone, at the end of April, there were almost 160,000 confirmed cases with more than 20,000 deaths. This has undoubtedly had significant physical and economical impact on the public. Healthcare workers are at high risk of developing life-threatening infectious diseases with increased exposure to patients' blood and bodily fluids. As such, health care workers arguably experience heightened anxiety and are predisposed to greater negative psycho-social impact from the current COVID-19 pandemic. The aim of this study is to evaluate the physical and psychological impact of COVID-19 on healthcare workers. This will be performed in two phases. In phase 1, investigators will collect information to evaluate the current psychiatric symptom profile (in particular, screening for anxiety or depression related symptoms), alcohol use, sleep-related complaints and overall well-being among healthcare workers who participate in this survey (with a focus on junior doctors). In addition the association of these mental health and behavioural parameters with the prevalence of stressful occasions, such as long-hours, unpredictability of work / redeployment, availability of personal protection equipment and concerns regarding family/relationship and self will be assessed. In phase 2, investigators will then reassess for the development or progression of psychiatric symptoms, use of alcohol and other substances, behavioural or interpersonal relationship changes as well as physical well-being at 6 weeks and 4- months. Physical well-being is assessed through the presence of suspected or confirmed COVID-19 infection and absence from work. Specifically, investigators will study the impact of variable provision of personal protection equipment (supply and training), extended working hours, and concern for well-being of family members, on work morale and anxiety levels. Another aim is also study the longer term mental health consequences of the current pandemic on health care workers.
Description: Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety.
Measure: Presence of anxiety at baseline Time: baselineDescription: Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression
Measure: Presence of depression at baseline Time: baselineDescription: Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression Higher score corresponding to more severe degree of anxiety.
Measure: Proportion of those who report a combined outcome of presence of anxiety or depression at the baseline as determined by screening questionnaires used. Time: baselineDescription: Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression
Measure: Change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study Time: 4 monthsDescription: Self reported, assessed based on the questions regarding the presence of symptoms with presence of either self reported positive test, or self-isolation of 7 or more days.
Measure: Change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 from baseline to the end of study Time: 4 monthsDescription: Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety.
Measure: Change in prevalence of anxiety from baseline Time: 4 monthsDescription: Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression
Measure: Change in prevalence of depression from baseline Time: 4 months followupDescription: This is based on questions derived from the Insomnia Severity Index Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)
Measure: Prevalence of sleep-related issues at baseline Time: At baselineDescription: Insomnia Severity Index Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)
Measure: Change in prevalence of sleep-related issues from baseline Time: 4-month follow-upDescription: Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)
Measure: Prevalence of a combined outcome of presence of anyone of anxiety, depression or sleep related issues at baseline. Time: baselineDescription: This is based on questions derived from the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS). Scores of 7-17 represent probable depression or anxiety; Scores of 18-20 suggest possible depression or anxiety.
Measure: Proportion of those with low mental wellbeing at baseline Time: baselineDescription: Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS). Scores of 7-17 represent probable depression or anxiety; Scores of 18-20 suggest possible depression or anxiety
Measure: Change in proportion of those with low mental wellbeing from baseline to the end of study. Time: 4-month follow-upDescription: Self-reported measures through responses to direct questions relevant to work-related practices in the survey
Measure: Prevalence of those who report concern related to work-place practices. Time: At baselineDescription: Self-reported measures through responses to direct questions relevant to work-related practices in the survey
Measure: Change in the prevalence from baseline of those who report concern related to work-place practices. Time: 6-weekDescription: Self-reported measures through responses to direct questions relevant to work-related practices in the survey
Measure: Change in the prevalence from baseline of those who report concern related to work-place practices. Time: 4 monthsDescription: Self-reported measures through responses to survey questions
Measure: Change in behavioural habits, such as smoking and alcohol intake from baseline to the end of study Time: 4-month follow-upDescription: Self reported, based on the presence of symptoms with either self reported positive test, or self-isolation of 7 or more days.
Measure: Proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 Time: BaselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports